TIAA Trust National Association Acquires 397 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

TIAA Trust National Association lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,566 shares of the company’s stock after purchasing an additional 397 shares during the period. TIAA Trust National Association’s holdings in IDEXX Laboratories were worth $1,385,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IDXX. Patron Partners LLC lifted its holdings in IDEXX Laboratories by 2.7% during the fourth quarter. Patron Partners LLC now owns 765 shares of the company’s stock worth $425,000 after buying an additional 20 shares during the period. NewEdge Wealth LLC lifted its stake in shares of IDEXX Laboratories by 3.1% during the 4th quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock worth $366,000 after purchasing an additional 20 shares during the last quarter. Manchester Capital Management LLC boosted its position in IDEXX Laboratories by 11.9% during the fourth quarter. Manchester Capital Management LLC now owns 188 shares of the company’s stock valued at $104,000 after purchasing an additional 20 shares in the last quarter. Atomi Financial Group Inc. grew its stake in IDEXX Laboratories by 3.4% in the first quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock valued at $344,000 after purchasing an additional 21 shares during the last quarter. Finally, Valley National Advisers Inc. raised its holdings in IDEXX Laboratories by 84.6% in the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after purchasing an additional 22 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on IDXX shares. Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Morgan Stanley dropped their price target on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, Barclays dropped their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $586.63.

Insider Activity

In related news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now owns 161 shares of the company’s stock, valued at approximately $87,068.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX stock traded up $5.98 during trading on Monday, hitting $474.18. 245,994 shares of the company traded hands, compared to its average volume of 472,180. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. The company has a market cap of $39.16 billion, a PE ratio of 45.32, a P/E/G ratio of 3.83 and a beta of 1.32. The stock’s 50-day simple moving average is $499.60 and its 200 day simple moving average is $519.50. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.